Mammographic density and risk of second breast cancer after ductal carcinoma in situ

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 10, 2010, Pages 2488-2495

  Habel, Laurel A ^a   Capra, Angela M ^a   Achacoso, Ninah S ^a   Janga, Aradhana ^a   Acton, Luana ^a   Puligandla, Balaram ^b   Quesenberry Jr , Charles P ^a  

^a DIVISION OF RESEARCH   (United States)

^b Kaiser Permanente ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER INVASION; CANCER RISK; CONSERVATIVE TREATMENT; DENSITY; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; SECOND CANCER;

ADULT; BREAST NEOPLASMS; CALIFORNIA; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 77958064382     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0769     Document Type: Article

References (48)

1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
2. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008.
3. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443-8.
4. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J 2006;12:20-7.
5. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-52.
6. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
7. Frykberg ER, Masood S, Copeland EM3, Bland KI. Ductal carcinoma in situ of the breast. Surg Gynecol Obstet 1993;177:425-40.
8. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69-75. (Pubitemid 27026805)
9. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
10. Gill JK, Maskarinec G, Pagano I, Kolonel LN. The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res 2006;8:R30.
11. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008;10:201.
12. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987;9:146-74.
13. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8.
14. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6. (Pubitemid 24081874)
15. Greendale GA, Reboussin BA, Sie A, et al, Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9.
16. McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009;27:6135-43.
17. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.
18. Greendale GA, Huang MH, Ursin G, et al. Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 2007;105:337-46. (Pubitemid 47596443)
19. Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 2004;96:1467-72. (Pubitemid 39429671)
20. Hwang ES, Miglioretti DL, Ballard-Barbash R, Weaver DL, Kerlikowske K. Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 2007;16:2587-93. (Pubitemid 351196313)
21. Gordon NP, Kaplan GA. Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente. Adv Health Econ Health Serv Res 1991;12:19-39.
22. Hiatt RA, Friedman GD. The frequency of kidney and urinary tract diseases in a defined population. Kidney Int 1982;22:63-8.
23. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-10.
24. Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol 1987;148:1087-92. (Pubitemid 17083062)
25. Prentice RL, Kalbfleisch JD, Peterson AV Jr., Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
26. Kalbfleisch JD, Prentice JL. The statistical analysis of failure time data. John Wiley and Sons, New York, 1980;167-8.
27. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993;12:737-51.
28. Byrne C. Studying mammographic density: implications for understanding breast cancer. J Natl Cancer Inst 1997;89:531-3.
29. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
30. Saftlas AF, Wolfe JN, Hoover RN, et al. Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol 1989;129:518-26.
31. Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833-8.
32. Park CC, Rembert J, Chew K, Moore D, Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys 2009;73:75-9.
33. Cil T, Fishell E, Hanna W, et al. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 2009;115:5780-7.
34. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
35. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
36. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City NY, United States). Cancer Causes Control 1995;6:431-8.
37. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208. (Pubitemid 23269083)
38. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-9.
39. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-24.
40. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35. (Pubitemid 23269068)
41. Trichopoulos D, Lipman RD. Mammary gland mass and breast cancer risk. Epidemiology 1992;3:523-6.
42. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med 2000;160:953-8.
43. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999;86:429-38. (Pubitemid 29347405)
44. Solin LJ, Fourquet A, Vicini FA, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001;50:991-1002.
45. Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1998;7:689-96.
46. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009;27:1362-7.
47. White E, Velentgas P, Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-10. (Pubitemid 28304158)
48. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.